aXichem AB (publ), provider of innovative natural analogue ingredients for the nutraceutical market, is pleased to announce a new order for its unique phenylcapsaicin product, aXivite^®, placed by Res Pharma, Italy, one of the company's key distributors. The ordered volume will be used for product development with two individual producers, and has an order value of 120 KSEK. It signifies the growing interest in aXivite and its expansion on the Italian market into two new product lines, that are expected to hit the market in the second half of this year. Italy represents almost 30% of the European market value for food supplements according to data from statista.com.

“Res Pharma has been proactively working to promote and increase market awareness of the outstanding benefits of aXivite, collaborating closely with R&D professionals to ensure optimal product performance. This order highlights the distributor's success in fostering interest in the market and driving growth for aXichem's offerings supporting our plans and objectives,” says Lucas Altepost, VP and VP Sales and Marketing at aXichem.

About phenylcapsaicin and aXivite

aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.

The information was submitted, through the care of the contact person below, for publication on 24 April 2023, at 08:30 AM CET.